Work

Development of 2-(5,6,7-Trifluoro-1H-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer

Year: 2021

Type: article

Source: Journal of Medicinal Chemistry

DOI: 10.1021/acs.jmedchem.1c00681

Institutions: University of British Columbia, Vancouver Prostate Centre, Koç University, Simon Fraser University, Oregon Health & Science University, OHSU Knight Cancer Institute

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: U.S. Department of Defense, Prostate Cancer Canada, Canadian Institutes of Health Research, Canadian Cancer Society Research Institute

Awards: G2052260643, G296494197, G739786069, G7835445324, DEVELOPEMNT OF NOVEL DRUGS THAT TARGET COACTIVATION SITES OF THE ANDROGEN RESEPTOR FOR TREATMENT OF ANTIANDROGEN0RESISTANT PROSTATE CANCER

OpenAlex ID: W3205225556

FWCI: 1.597

Cites: 42

Cited by: 13

Related to: 10